LRMR Larimar Therapeutics
- 6.170
- +0.060+0.98%
- 6.170
- 0.0000.00%
Larimar Therapeutics News
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Blue Owl Capital Holdings LP(6.53%)
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(8.7%),Janus Henderson Biotech Innovation Master Fund Ltd(7.5%)
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Verition Fund Management LLC(0.9%),Nicholas Maounis(0.9%)
Larimar Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-THE GOLDMAN SACHS GROUP, INC.(7.0 %),GOLDMAN SACHS & CO. LLC(7.0 %)
Larimar Therapeutics | 10-Q: Q3 2024 Earnings Report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Larimar Therapeutics | 10-Q: Q2 2024 Earnings Report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Flynn James E
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hamilton Thomas Edward
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Truitt Joseph
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SHERMAN JEFFREY W
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director LEFF JONATHAN S
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director THOMAS FRANK E
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | EFFECT: Others
Larimar Therapeutics | CORRESP: CORRESP
No Data